Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI

By
Peter Wang
Kui You
Zi Wei Chia
Lissa Hooi
Li Ming Chong
De Hoe Chye
Angelina Moh
Ze Yong Lee
Ethan Lim
Alrick Zi Xin Kok
Stephen Chua
Isaiah Zhuang
Ella Chang
Boon Huan Tan
Gladys Gek Yen Tan
Shawn Vasoo
Conrad E. Z. Chan
Edward Kai-Hua Chow
Dean Ho
June 2, 2026
0 min

Frontiers In Digital Health

Overview

This report discusses the use of IDentif.AI to identify drug combinations that enhance the efficacy of sotrovimab (STV) against the XBB variant of SARS-CoV-2. The study found that STV combined with EIDD-1931 and GS-441524 significantly improved potency and reduced the in vitro EC50 of STV.

Background

The emergence of SARS-CoV-2 variants has led to declining efficacy of existing treatments, necessitating the development of new strategies. Monoclonal antibodies like sotrovimab have seen reduced effectiveness against variants such as XBB, prompting the need for innovative approaches to restore their utility. Utilizing AI-driven platforms like IDentif.AI may offer a pathway to optimize existing therapies through strategic drug combinations.

Data Highlights

No numerical data available in the provided source material.

Key Findings

IDentif.AI identified effective drug combinations to enhance STV efficacy.
Combinations of STV with EIDD-1931 and GS-441524 showed synergistic effects against the XBB variant.
The in vitro EC50 of STV was reduced by up to 7-fold with these combinations.
AI-driven optimization can repurpose existing therapeutics for improved treatment outcomes.
Emerging variants have led to the revocation of EUAs for some monoclonal antibodies.

Clinical Implications

The findings suggest that combining existing monoclonal antibodies with other agents may restore their effectiveness against new variants. Clinicians should consider the potential of AI-driven platforms for optimizing treatment strategies in the face of evolving viral challenges.

Conclusion

The study highlights the potential of IDentif.AI in enhancing the efficacy of monoclonal antibodies against emerging COVID-19 variants, providing a framework for future therapeutic strategies.